NCT04288362 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bodenheimer T, Wagner EH, Grumbach K
Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002 Oct 16;288(15):1909-14.
Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R
Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev. 2015 Mar 3;(3):CD010523. doi: 10.1002/14651858.CD010523.pub2. Review.
Hibbard JH, Stockard J, Mahoney ER, Tusler M
Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26.
Wagner EH, Austin BT, Von Korff M
Organizing care for patients with chronic illness. Milbank Q. 1996;74(4):511-44. Review.

The Patient Activation Through Community Empowerment/Engagement for Diabetes Management (PACE-D) Protocol: A Non-randomised Controlled Trial of Personalised Care and Support Planning for Persons Living With Diabetes

Details for clinical trial NCT04288362

Clinical trial NCT04288362 - References